From Original Antigenic Sin to the Universal Influenza Virus Vaccine

Trends in Immunology

Volumn 39, Issue 1, 2018, Pages 70-79

  Henry, Carole ^a   Palm, Anna Karin E ^a   Krammer, Florian ^b   Wilson, Patrick C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; INFLUENZA VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANTIBODY RESPONSE; HUMAN; IMMUNITY; IMMUNOLOGICAL MEMORY; INFLUENZA; INFLUENZA VACCINATION; NONHUMAN; REVIEW; ANIMAL; ANTIBODY SPECIFICITY; ANTIGENIC VARIATION; ENVIRONMENTAL EXPOSURE; HUMORAL IMMUNITY; IMMUNOLOGY; METABOLISM; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRUS INFECTION; PHYSIOLOGY; VACCINATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY DIVERSITY; ANTIGENIC VARIATION; ANTIGENS, VIRAL; ENVIRONMENTAL EXPOSURE; HUMANS; IMMUNITY, HUMORAL; IMMUNODOMINANT EPITOPES; IMMUNOLOGIC MEMORY; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION;

EID: 85028548934     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2017.08.003     Document Type: Review

References (94)

1. Gerdil, C., The annual production cycle for influenza vaccine. Vaccine 21 (2003), 1776–1779.
2. Air, G.M., Sequence relationships among the hemagglutinin genes of 12 subtypes of influenza A virus. Proc. Natl. Acad. Sci. U. S. A. 78 (1981), 7639–7643.
3. Tong, S., et al. New world bats harbor diverse influenza A viruses. PLoS Pathog., 9, 2013, e1003657.
4. Zhu, X., et al. Hemagglutinin homologue from H17N10 bat influenza virus exhibits divergent receptor-binding and pH-dependent fusion activities. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 1458–1463.
5. Rota, P.A., et al. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 175 (1990), 59–68.
6. Krystal, M., et al. Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes. Proc. Natl. Acad. Sci. U. S. A. 79 (1982), 4800–4804.
7. Andrews, S.F., et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci. Transl. Med., 7, 2015, 316ra192.
8. Krammer, F., Palese, P., Advances in the development of influenza virus vaccines. Nat. Rev. Drug Discov. 14 (2015), 167–182.
9. Krammer, F., Palese, P., Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. 3 (2013), 521–530.
10. Krammer, F., et al. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr. Top. Microbiol. Immunol. 386 (2015), 301–321.
11. Cobey, S., Hensley, S.E., Immune history and influenza virus susceptibility. Curr. Opin. Virol. 22 (2017), 105–111.
12. Francis, T. Jr., On the doctrine of original antigenic sin. Proc. Am. Philos. Soc. 104 (1960), 572–578.
13. Davenport, F.M., et al. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J. Exp. Med. 98 (1953), 641–656.
14. Davenport, F.M., et al. Epidemiology of influenza; comparative serological observations in England and the United States. Lancet 269 (1955), 469–474.
15. Rajendran, M., et al. Analysis of anti-influenza virus neuraminidase antibodies in children, adults, and the elderly by ELISA and enzyme inhibition: evidence for original antigenic sin. MBio, 8, 2017, e02281-16.
16. Zarnitsyna, V.I., et al. Masking of antigenic epitopes by antibodies shapes the humoral immune response to influenza. Philos. Trans R. Soc. Lond. B Biol. Sci., 370, 2015, 20140248.
17. Bergstrom, J.J., et al. Epitope-specific suppression of IgG responses by passively administered specific IgG: evidence of epitope masking. Front. Immunol., 8, 2017, 238.
18. Gulati, U., et al. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine 23 (2005), 1414–1425.
19. DiLillo, D.J., et al. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J. Clin. Invest. 126 (2016), 605–610.
20. Henry Dunand, C.J., et al. Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection. Cell Host Microbe 19 (2016), 800–813.
21. Fonville, J.M., et al. Antibody landscapes after influenza virus infection or vaccination. Science 346 (2014), 996–1000.
22. Kim, J.H., et al. Original antigenic sin responses to influenza viruses. J. Immunol. 183 (2009), 3294–3301.
23. Fazekas de St, G., Webster, R.G., Disquisitions of original antigenic sin. I. Evidence in man. J. Exp. Med. 124 (1966), 331–345.
24. Virelizier, J.L., et al. Antibody responses to antigenic determinants of influenza virus hemagglutinin. II. Original antigenic sin: a bone marrow-derived lymphocyte memory phenomenon modulated by thymus-derived lymphocytes. J. Exp. Med. 140 (1974), 1571–1578.
25. Kim, J.H., et al. Strategies to alleviate original antigenic sin responses to influenza viruses. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 13751–13756.
26. Lessler, J., et al. Evidence for antigenic seniority in influenza A (H3N2) antibody responses in southern China. PLoS Pathog., 8, 2012, e1002802.
27. Kucharski, A.J., et al. Estimating the life course of influenza A(H3N2) antibody responses from cross-sectional data. PLoS Biol., 13, 2015, e1002082.
28. Miller, M.S., et al. Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci. Transl. Med., 5, 2013, 198ra107.
29. Bodewes, R., et al. Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands. Clin. Vaccine Immunol. 18 (2011), 469–476.
30. Gostic, K.M., et al. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science 354 (2016), 722–726.
31. Nachbagauer, R., et al. Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nat. Immunol. 18 (2017), 464–473.
32. Francis, T. Jr., et al. Experience with vaccination against influenza in the spring of 1947: a preliminary report. Am. J. Public Health Nations Health 37 (1947), 1013–1016.
33. Li, Y., et al. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J. Exp. Med. 210 (2013), 1493–1500.
34. Linderman, S.L., et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 15798–15803.
35. Petrie, J.G., et al. Antibodies against the current influenza A(H1N1) vaccine strain do not protect some individuals from infection with contemporary circulating influenza A(H1N1) virus strains. J. Infect. Dis. 214 (2016), 1947–1951.
36. Bodewes, R., et al. Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J. Virol. 85 (2011), 2695–2702.
37. Linderman, S.L., Hensley, S.E., Antibodies with ‘original antigenic sin’ properties are valuable components of secondary immune responses to influenza viruses. PLoS Pathog., 12, 2016, e1005806.
38. Wrammert, J., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453 (2008), 667–671.
39. O'Donnell, C.D., et al. Humans and ferrets with prior H1N1 influenza virus infections do not exhibit evidence of original antigenic sin after infection or vaccination with the 2009 pandemic H1N1 influenza virus. Clin. Vaccine Immunol. 21 (2014), 737–746.
40. Viboud, C., et al. Age- and sex-specific mortality associated with the 1918–1919 influenza pandemic in Kentucky. J. Infect. Dis. 207 (2013), 721–729.
41. Hancock, K., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361 (2009), 1945–1952.
42. Worobey, M., et al. Genesis and pathogenesis of the 1918 pandemic H1N1 influenza A virus. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 8107–8112.
43. Henry Dunand, C.J., et al. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J. Clin. Invest. 125 (2015), 1255–1268.
44. Li, G.M., et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 9047–9052.
45. Wrammert, J., et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208 (2011), 181–193.
46. Huang, K.Y., et al. Focused antibody response to influenza linked to antigenic drift. J. Clin. Invest. 125 (2015), 2631–2645.
47. Skehel, J.J., Wiley, D.C., Influenza haemagglutinin. Vaccine 20 (2002), S51–S54.
48. Iba, Y., et al. Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses. J. Virol. 88 (2014), 7130–7144.
49. Dreyfus, C., et al. Highly conserved protective epitopes on influenza B viruses. Science 337 (2012), 1343–1348.
50. Schmidt, A.G., et al. Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 264–269.
51. Tsibane, T., et al. Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. PLoS Pathog., 8, 2012, e1003067.
52. Ekiert, D.C., et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489 (2012), 526–532.
53. Lee, P.S., et al. Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 17040–17045.
54. Whittle, J.R., et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 14216–14221.
55. Ekiert, D.C., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324 (2009), 246–251.
56. Sui, J., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16 (2009), 265–273.
57. Graves, P.N., et al. Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology 126 (1983), 106–116.
58. Wang, T.T., et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog., 6, 2010, e1000796.
59. Ekiert, D.C., et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333 (2011), 843–850.
60. Friesen, R.H., et al. A common solution to group 2 influenza virus neutralization. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 445–450.
61. Tan, G.S., et al. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J. Virol. 88 (2014), 13580–13592.
62. Tan, G.S., et al. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J. Virol. 86 (2012), 6179–6188.
63. Corti, D., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333 (2011), 850–856.
64. Kallewaard, N.L., et al. Structure and function analysis of an antibody recognizing all influenza A subtypes. Cell 166 (2016), 596–608.
65. Joyce, M.G., et al. Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses. Cell 166 (2016), 609–623.
66. Moody, M.A., et al. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One, 6, 2011, e25797.
67. Margine, I., et al. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J. Virol. 87 (2013), 4728–4737.
68. Liu, L., et al. Induction of broadly cross-reactive stalk-specific antibody responses to influenza group 1 and group 2 hemagglutinins by natural H7N9 virus infection in humans. J. Infect. Dis. 215 (2017), 518–528.
69. Miller, M.S., et al. 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J. Infect. Dis. 207 (2013), 98–105.
70. Sui, J., et al. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin. Infect. Dis. 52 (2011), 1003–1009.
71. Sangster, M.Y., et al. B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Clin. Vaccine Immunol. 20 (2013), 867–876.
72. Thomson, C.A., et al. Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem. Front. Immunol., 3, 2012, 87.
73. Ellebedy, A.H., et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 13133–13138.
74. Krammer, F., The quest for a universal flu vaccine: headless HA 2.0. Cell Host Microbe 18 (2015), 395–397.
75. Krammer, F., Novel universal influenza virus vaccine approaches. Curr. Opin. Virol. 17 (2016), 95–103.
76. Sagawa, H., et al. The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J. Gen. Virol. 77 (1996), 1483–1487.
77. Steel, J., et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio, 1, 2010, e00018-10.
78. Wohlbold, T.J., et al. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses. Vaccine 33 (2015), 3314–3321.
79. Mallajosyula, V.V., et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E2514–E2523.
80. Yassine, H.M., et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21 (2015), 1065–1070.
81. Impagliazzo, A., et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349 (2015), 1301–1306.
82. Valkenburg, S.A., et al. Stalking influenza by vaccination with pre-fusion headless HA mini-stem. Sci. Rep., 6, 2016, 22666.
83. Krammer, F., et al. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87 (2013), 6542–6550.
84. Krammer, F., et al. H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J. Virol. 88 (2014), 2340–2343.
85. Margine, I., et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J. Virol. 87 (2013), 10435–10446.
86. Nachbagauer, R., et al. Hemagglutinin stalk immunity reduces influenza virus replication and transmission in ferrets. J. Virol. 90 (2015), 3268–3273.
87. Goff, P.H., et al. Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One, 8, 2013, e79194.
88. Nachbagauer, R., Krammer, F., Universal influenza virus vaccines and therapeutic antibodies. Clin. Microbiol. Infect. 23 (2017), 222–228.
89. Nachbagauer, R., et al. Age dependence and isotype specificity of influenza virus hemagglutinin stalk-reactive antibodies in humans. MBio, 7, 2016, e01996-15.
90. Gagnon, A., et al. Is antigenic sin always ‘original?’ Re-examining the evidence regarding circulation of a human H1 influenza virus immediately prior to the 1918 Spanish flu. PLoS Pathog., 11, 2015, e1004615.
91. Andrews, S.F., et al. High preexisting serological antibody levels correlate with diversification of the influenza vaccine response. J. Virol. 89 (2015), 3308–3317.
92. Krammer, F., et al. An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clin. Vaccine Immunol. 21 (2014), 1153–1163.
93. Nachbagauer, R., et al. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J. Virol. 88 (2014), 13260–13268.
94. Halliley, J.L., et al. High-affinity H7 head and stalk domain-specific antibody responses to an inactivated influenza H7N7 vaccine after priming with live attenuated influenza vaccine. J. Infect. Dis. 212 (2015), 1270–1278.